Show table of contents · 8 sections▾
This is a plain-English explainer, not legal advice. Only a licensed attorney representing you can evaluate the specific facts of your case.
The Ozempic/Mounjaro Litigation at a Glance
GLP-1 receptor agonist drugs — Ozempic and Rybelsus (semaglutide, Novo Nordisk), Wegovy (semaglutide for weight loss, Novo Nordisk), Mounjaro and Zepbound (tirzepatide, Eli Lilly) — have surged in popularity for both type 2 diabetes and weight loss. Plaintiffs allege that manufacturers failed to warn about severe gastrointestinal complications including gastroparesis (stomach paralysis), intestinal blockage, and severe cyclic vomiting.
MDL 3094 Formation and Status
The JPML formed MDL 3094 (In re Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation) in February 2024, assigning it to Judge Gene E.K. Pratter in the Eastern District of Pennsylvania. As of 2026:
- Thousands of cases consolidated.
- Bellwether selection process underway.
- Case-specific discovery in early phase.
- Master complaint filed against Novo Nordisk and Eli Lilly.
Alleged Failure to Warn
Plaintiffs allege manufacturers knew or should have known that GLP-1 drugs cause:
- Gastroparesis: Delayed gastric emptying — food remains in the stomach for hours, causing chronic nausea, vomiting, weight loss, and severe pain.
- Intestinal blockage: Ileus, small bowel obstruction requiring hospitalization or surgery.
- Severe cyclic vomiting: Episodic vomiting requiring hospitalization.
- Aspiration during surgery: Anesthesiologists now recommend stopping GLP-1s before surgery due to aspiration risk.
These complications were not adequately disclosed on original product labels. Some warnings have been added over time as regulatory pressure has grown.
Diagnosis Documentation
Gastroparesis diagnosis typically requires:
- Gastric emptying study (radionuclide scintigraphy).
- Documented delayed emptying at 4 hours (>10% retention).
- Clinical symptoms: chronic nausea, vomiting, early satiety, abdominal pain.
- Exclusion of mechanical obstruction.
Funding Availability
Reputable funders underwrite filed MDL 3094 cases with:
- Documented GLP-1 drug use (Ozempic, Mounjaro, Wegovy, Zepbound).
- Gastroparesis or severe GI complication diagnosis.
- Represented by MDL-experienced counsel.
Case Value Considerations
The MDL is early — no bellwether verdicts yet. Advance sizing is conservative pending case-value data. Plaintiffs with severe complications (multiple hospitalizations, surgeries, ongoing disability) will likely have higher case values than those with milder GI complaints.
The Bottom Line
The Ozempic/Mounjaro litigation is one of the largest and fastest-growing mass torts in the U.S. legal system. If you took a GLP-1 drug and developed gastroparesis or severe GI complications requiring diagnosis and treatment, consult an MDL-experienced attorney. Pre-settlement funding is available for filed cases with appropriate documentation.
At Instabridge Funding, we work with plaintiff attorneys across all fifty states — attorney-founded, non-recourse, and transparently priced. If your case is filed and you would like a fair pre-settlement offer, apply through our portal and your attorney will hear back within one business day.
Frequently asked questions
Ozempic and Rybelsus (semaglutide), Wegovy (semaglutide for weight loss), Mounjaro (tirzepatide), and Zepbound (tirzepatide for weight loss).
Delayed gastric emptying — food remains in the stomach for hours, causing chronic nausea, vomiting, weight loss, and abdominal pain.
Via a gastric emptying study (radionuclide scintigraphy) documenting delayed emptying at 4 hours (>10% retention), plus clinical symptoms.
Thousands of cases and growing rapidly as of 2026. This is one of the fastest-growing MDLs in the country.
Yes, for filed cases with documented drug use, gastroparesis diagnosis, and MDL-experienced counsel.
Cases without documented gastroparesis diagnosis or hospitalization typically have lower case value. Talk to your attorney about the specific factual profile.
Never make medical decisions based on litigation. Consult your prescribing physician about any concerns.
